Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment

James A. Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853, USA.
Journal of Clinical Microbiology (Impact Factor: 3.99). 02/1997; 35(1):111-6.
Source: PubMed


In specific-pathogen-free dogs experimentally infected with Borrelia burgdorferi by tick exposure, treatment with high doses of amoxicillin or doxycycline for 30 days diminished but failed to eliminate persistent infection. Although joint disease was prevented or cured in five of five amoxicillin- and five of six doxycycline-treated dogs, skin punch biopsies and multiple tissues from necropsy samples remained PCR positive and B. burgdorferi was isolated from one amoxicillin- and two doxycycline-treated dogs following antibiotic treatment. In contrast, B. burgdorferi was isolated from six of six untreated infected control dogs and joint lesions were found in four of these six dogs. Serum antibody levels to B. burgdorferi in all dogs declined after antibiotic treatment. Negative antibody levels were reached in four of six doxycycline- and four of six amoxicillin-treated dogs. However, in dogs that were kept in isolation for 6 months after antibiotic treatment was discontinued, antibody levels began to rise again, presumably in response to proliferation of the surviving pool of spirochetes. Antibody levels in untreated infected control dogs remained high.

Download full-text


Available from: Reinhard K Straubinger,
    • "Unfortunately, continued antibiotic treatment is not recommended as its long-term effectiveness has not been observed or proven (Delong et al. 2012; Stanek et al. 2012). The increasing trend with new and relapsing Lyme disease cases was noted and attributed mainly to inadequate prevention, ineffective therapy and/or bacterial persistency (Straubinger et al. 1997; Bockenstedt et al. 2002; Peltomaa et al. 2003; Hodzic et al. 2008; Feng et al. 2014). "
    [Show abstract] [Hide abstract]
    ABSTRACT: AimsLittle is known about the effects of phytochemicals against Borrelia sp. causing Lyme disease. Current therapeutic approach to this disease is limited to antibiotics. This study examined the anti-borreliaea efficacy of several plant-derived compounds and micronutrients.Methods and ResultsWe tested the efficacy of 15 phytochemicals and micronutrients against three morphological forms of Borrelia burgdoferi and Borrelia garinii: spirochetes, latent rounded forms and biofilm. The results showed that the most potent substances against the spirochete and rounded forms of Borrelia burgdorferi and Borrelia garinii were cis-2-decenoic acid, baicalein, monolaurin, and kelp (iodine); whereas, only baicalein and monolaurin revealed significant activity against the biofilm. Moreover, cis-2-decenoic acid, baicalein, and monolaurin did not cause statistically significant cytotoxicity to human HepG2 cells up to 125 μg ml−1, and kelp up to 20 μg ml−1.Conclusions The most effective antimicrobial compounds against all morphological forms of the two tested Borrelia sp. were baicalein and monolaurin. This might indicate that the presence of fatty acid and phenyl groups is important for comprehensive antibacterial activity.Significance and Impact of the StudyThis study reveals the potential of phytochemicals as an important tool in the fight against the species of Borrelia causing Lyme disease.This article is protected by copyright. All rights reserved.
    Journal of Applied Microbiology 10/2015; DOI:10.1111/jam.12970 · 2.48 Impact Factor
  • Source
    • "Although animals do not experience symptoms that might be judged to be PTLDS, in various animal models (mice, dogs and rhesus macaque monkeys), antibiotic therapy with doxycycline, ceftriaxone or tigecycline has not fully eradicated B. burgdorferi, as determined by methods including xenodiagnosis, although viable organisms have not been able to be cultured in conventional culture media.11,12,13,14 Others have raised concerns about such findings, including the use of high concentration inocula and the use of stationary-phase organisms for infection, insufficient antibiotic dosing and other methodological issues, including concerns that rodents are a natural reservoir of B. burgdorferi and that studies of persistence would not approximate human infections.15,16 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although antibiotic treatment for Lyme disease is effective in the majority of cases, especially during the early phase of the disease, a minority of patients suffer from post-treatment Lyme disease syndrome (PTLDS). It is unclear what mechanisms drive this problem, and although slow or ineffective killing of Borrelia burgdorferi has been suggested as an explanation, there is a lack of evidence that viable organisms are present in PTLDS. Although not a clinical surrogate, insight may be gained by examining stationary-phase in vitro Borrelia burgdorferi persisters that survive treatment with the antibiotics doxycycline and amoxicillin. To identify drug candidates that can eliminate B. burgdorferi persisters more effectively, we screened an Food and Drug Administration (FDA)-approved drug library consisting of 1524 compounds against stationary-phase B. burgdorferi by using a newly developed high throughput SYBR Green I/propidium iodide (PI) assay. We identified 165 agents approved for use in other disease conditions that had more activity than doxycycline and amoxicillin against B. burgdorferi persisters. The top 27 drug candidates from the 165 hits were confirmed to have higher anti-persister activity than the current frontline antibiotics. Among the top 27 confirmed drug candidates from the 165 hits, daptomycin, clofazimine, carbomycin, sulfa drugs (e.g., sulfamethoxazole), and certain cephalosporins (e.g. cefoperazone) had the highest anti-persister activity. In addition, some drug candidates, such as daptomycin and clofazimine (which had the highest activity against non-growing persisters), had relatively poor activity or a high minimal inhibitory concentration (MIC) against growing B. burgdorferi. Our findings may have implications for the development of a more effective treatment for Lyme disease and for the relief of long-term symptoms that afflict some Lyme disease patients.
    Emerging Microbes and Infections 07/2014; 3(7):e49. DOI:10.1038/emi.2014.53 · 2.26 Impact Factor
  • Source
    • "Embers et al138 addressed several of the key issues identified by Wormser and Schwartz140 in their 2009 review that focused on studies by Bockenstedt et al,141 Hodzic et al,142 and Straubinger et al,143 all of which documented the persistence of Bb in the tissues of animals despite the antibiotic challenge. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Is chronic illness in patients with Lyme disease caused by persistent infection? Three decades of basic and clinical research have yet to produce a definitive answer to this question. This review describes known and suspected mechanisms by which spirochetes of the Borrelia genus evade host immune defenses and survive antibiotic challenge. Accumulating evidence indicates that Lyme disease spirochetes are adapted to persist in immune competent hosts, and that they are able to remain infective despite aggressive antibiotic challenge. Advancing understanding of the survival mechanisms of the Lyme disease spirochete carry noteworthy implications for ongoing research and clinical practice.
    International Journal of General Medicine 04/2013; 6:291-306. DOI:10.2147/IJGM.S44114
Show more